Ambarella’s Q2 FY2027: A Measured Beat on Non-GAAP Terms, a Guarded EPS Narrative, and a Cautious Revenue Forecast for Q3

In the voice of a veteran finance observer, with a dash of Matt Levine-style skepticism and curiosity about the numbers behind the numbers.

The ticker AMBA delivered a quarterly update that reads more like a careful ledger entry than a fireworks show. Revenue and margins moved in the right direction, but the story hinges on the distinction between GAAP and non‑GAAP results, the one-time credit that softened reported expenses, and a Q3 revenue forecast that sits squarely in the 115 to 124 million range. For investors watching EPS, that split between GAAP losses and non-GAAP profits remains the core drama—and a reminder that earnings per share is not the same thing as a cash dividend, even when the accounting makes them look similar.

A few SEO-friendly anchors for the rest of the discussion: AMBA is the ticker, EPS is reported both GAAP and non‑GAAP, there’s an implied earnings surprise depending on the model, and the revenue forecast for the next quarter frames how Wall Street might model the stock going forward.

What Ambarella reported for the quarter

Revenue: $108.1 million in the second quarter of fiscal 2027, up 13.2% from $95.5 million a year earlier. For the six months ended July 31, 2026, revenue was $208.5 million, up 14.9% versus the prior year period.
GAAP gross margin: 57.7% for the quarter; six months GAAP gross margin was 58.0%.
GAAP net loss (EPS): $6.7 million loss in the quarter, or $0.15 loss per diluted share. For the six months, GAAP net loss was $24.8 million, or $0.57 per diluted share.
Non-GAAP metrics: Gross margin on a non-GAAP basis was 59.3% for the quarter, 59.6% for the six months. Non-GAAP net income was $8.2 million, or $0.18 per diluted share in Q2; six months non-GAAP net income was $13.3 million, or $0.30 per diluted share.
One-time items: A one-time $9.0 million reduction in GAAP R&D expense related to the release of a deposit liability after a development-project termination, treated as non-recurring and excluded from non-GAAP results.
Guidance (Q3 FY2027): Revenue between $115.0 million and $124.0 million. Non-GAAP gross margin guidance of 59.0% to 60.0%. Non-GAAP operating expenses expected to be between $56.5 million and $59.5 million.
Balance sheet snippet: Total cash, cash equivalents and marketable debt securities on hand at the end of Q2 was disclosed in the press release, though the excerpt provided ends with “$27” and does not display the full figure.

Interpretation: what the numbers portend

The revenue cadence looks modestly constructive. Ambarella’s Q2 growth of 13.2% year over year, and 14.9% for the six-month period, suggests the company is growing in line with—or slightly ahead of—its target markets for edge AI semiconductor solutions. The GAAP gap versus non-GAAP performance remains a recurring theme: non-GAAP net income of $0.18 per share on revenue of $108.1 million signals that the underlying business is generating operating leverage when you strip out stock-based compensation, acquisition-related costs, and, in this quarter, a one-time R&D adjustment.

The one-time $9.0 million R&D credit—related to a deposit liability that arose after terminating a development project—highlights a familiar dynamic: management can materially alter the GAAP figures via non-recurring items, while non-GAAP reporting paints a more stable, repeatable earnings picture. The street should be mindful of these adjustments when modeling EPS consensus versus reported EPS. In other words, the “earnings surprise” question depends on whether you’re looking at GAAP or non-GAAP, and on which guidance metric you trust as a forecasting anchor.

From a margin perspective, Ambarella is defending a mid-to-high 50s GAAP gross margin and roughly 59% non-GAAP gross margin. That 1–2 point delta between GAAP and non-GAAP margins is a reminder that stock-based compensation and acquisition costs matter, not just on the income line but in how investors understand operating efficiency. The Q3 guidance implies continued revenue growth but a careful control of operating expenses, which bodes well if product mix shifts toward higher-margin offerings or if a larger portion of revenue comes from non-GAAP-boosting items that don’t recur in the next quarter.

Outlook, risk, and what peers might watch

Ambarella’s forecast for Q3—revenue in the $115–$124 million band with a non-GAAP gross margin near 59–60%—suggests management expects ongoing demand for its edge AI solutions, but with continued deliberate cost discipline. For sector peers, the message is twofold: first, the non-GAAP framework remains a potent tool to illustrate underlying profitability, and second, one-time accounting items can distort GAAP trajectories in ways that matter for headline EPS readings but may not reflect cash generation or operating health.

Investors should watch how the company balances R&D investments with the desire to monetize its IP and product suite. If Ambarella can sustain non-GAAP profitability while growing revenue into mid-teens, it could set a template for other AI semiconductor players who must reconcile R&D intensity with the need for visible, repeatable earnings power.

Bottom line

Ambarella’s second-quarter results illustrate a company navigating a competitive AI-accelerated hardware landscape with disciplined cost management and a careful approach to earnings reporting. The gap between GAAP loss and non-GAAP profit remains central to how investors will price the stock going forward, especially as the market absorbs guidance that is modestly constructive but not transformative.

For now, the AMBA story leans toward a cautious depreciation of risk and a modest re-rating on non-GAAP profitability. If the company can translate Q3 guidance into sustained top-line momentum and keep non-GAAP margins firm, peers in the edge AI space—where the margin environment is as important as the headline top line—will likely take note. The real question is whether Ambarella can convert this quarter’s non-GAAP gains into a durable path to cash-positive growth, or if the one-time R&D adjustment will prove to be a temporary footnote in a longer narrative about market share and pricing power.